Want to see MLTX full AI Analyst Report?
MLTX Stock Chart & Stats
$15.56
$0.84(4.42%)
At close: 4:00 PM EDT
$15.56
$0.84(4.42%)
Day’s Range― - ―
52-Week Range$8.90 - $23.29
Previous CloseN/A
Volume138.32K
Average Volume (3M)1.84M
Market Cap
$878.30M
Enterprise Value$1.00B
Total Cash (Recent Filing)$537.03M
Total Debt (Recent Filing)$101.53M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Nov 17, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding85,106,680
10 Day Avg. Volume1,988,553
30 Day Avg. Volume1,844,345
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-628.84
Enterprise Value/Ebitda-4.00
Forecast
1Y Price Target
$33.00Price Target Upside112.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressThe BLA submission is a major step toward potential commercialization of sonelokimab in a serious inflammatory skin disease. Regulatory progress can validate the lead asset, broaden future revenue opportunities, and establish a clearer path beyond the company’s current clinical-stage model.
Phase 3 EfficacyPositive Phase 3 results strengthen evidence that sonelokimab may provide clinically meaningful benefits in psoriatic arthritis. Replication across endpoints and indications could improve the asset’s competitive position, support regulatory filings, and expand its potential commercial opportunity.
Funding RunwaySubstantial liquidity and an indicated funding runway to mid-2028 give MoonLake capacity to advance multiple late-stage programs without an immediate need to disrupt development plans. This supports continued execution across inflammatory disease indications and reduces near-term funding pressure.
Bears Say
Pre-Revenue ModelThe absence of product revenue means MoonLake has not yet demonstrated commercial demand or an operating revenue base to offset research and development costs. Its financial profile therefore remains dependent on successful approvals and eventual commercialization of sonelokimab.
Worsening LossesThe widening net loss indicates that operating expenses are rising faster than any offsetting income, increasing the resources required to reach commercialization. Persistent losses can reduce financial flexibility and amplify the consequences of delays, weaker results, or additional development spending.
Cash BurnRapidly increasing cash consumption makes continued external funding important while MoonLake advances its pipeline. Even with available liquidity, sustained negative operating and free cash flow can pressure the balance sheet, limit capital allocation flexibility, and raise dilution or borrowing risk.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $8.90 and its highest was $23.29 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $878.30M.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 26 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Aug 10, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.918 by $0.078.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.78.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 85,106,680 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.918. Following the earnings report the stock price went down -5.093%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (112.08% Upside)
$33.00 (112.08% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 94%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 456.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.31%
12-Months-Change
Fundamentals
Return on Equity
-82.68%
Trailing 12-Months
Asset Growth
24.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$33.00
▲(112.08% Upside)
Technical Analysis
Ownership Overview
26.65% Insiders
1.78% Mutual Funds
0.27% Other Institutional Investors
70.14% Public Companies and
Individual Investors